Galecto, Inc.GLTOEarnings & Financial Report
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
Revenue
$213.0K
Gross Profit
N/A
Operating Profit
$-5.6M
Net Profit
$-5.3M
Gross Margin
N/A
Operating Margin
-2618.3%
Net Margin
-2506.1%
YoY Growth
-51.8%
EPS
$-4.92
Galecto, Inc. Q2 FY2024 Financial Summary
Galecto, Inc. reported revenue of $213.0K (down 51.8% YoY) for Q2 FY2024, with a net profit of $-5.3M (up 50.3% YoY) (-2506.1% margin).
Key Financial Metrics
| Total Revenue | $213.0K |
|---|---|
| Net Profit | $-5.3M |
| Gross Margin | N/A |
| Operating Margin | -2618.3% |
| Report Period | Q2 FY2024 |
Galecto, Inc. Annual Revenue by Year
Galecto, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $844.0K).
| Year | Annual Revenue |
|---|---|
| 2024 | $844.0K |
| 2023 | $1.7M |
Galecto, Inc. Quarterly Revenue & Net Profit History
Galecto, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $1.0M | +339.0% | $-200.7M | -20053.5% |
| Q4 FY2024 | $228.0K | -32.9% | $-6.7M | -2956.6% |
| Q3 FY2024 | $146.0K | -69.1% | $-3.9M | -2659.6% |
| Q2 FY2024 | $213.0K | -51.8% | $-5.3M | -2506.1% |
| Q1 FY2024 | $257.0K | -40.8% | $-5.5M | -2131.1% |
| Q4 FY2023 | $340.0K | +19.7% | $-6.5M | -1904.4% |
| Q3 FY2023 | $473.0K | +114.0% | $-8.1M | -1720.1% |
| Q2 FY2023 | $442.0K | +183.3% | $-10.7M | -2430.8% |
Income Statement
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $442000 | $473000 | $340000 | $257000 | $213000 | $146000 | $228000 | $1.0M |
| YoY Growth | 183.3% | 114.0% | 19.7% | -40.8% | -51.8% | -69.1% | -32.9% | 339.0% |
Balance Sheet
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $58.8M | $50.0M | $38.2M | $32.5M | N/A | $23.4M | $17.1M | $260.5M |
| Liabilities | $15.1M | $12.7M | $5.9M | $4.3M | N/A | $2.4M | $1.3M | $20.1M |
| Equity | $43.7M | $37.4M | $32.3M | $28.2M | $23.6M | $20.9M | $15.8M | $240.4M |
Cash Flow
| Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.8M | $-8.5M | $-11.5M | $-5.9M | $-4.1M | $-3.7M | $-4.9M | $566000 |